Limited therapeutic options are available after relapse of acute leukaemia following first reduced intensity conditioning haematopoietic stem cell transplantation (RIC1). A retrospective study on European Society for Blood and Marrow Transplantation (EBMT) registry data was performed on 234 adult patients with acute leukaemia who received a second RIC transplantation (RIC2) from 2000 to 2012 as a salvage treatment for relapse following RIC1. At the time of RIC2, 167 patients (71.4%) had relapsed or refractory disease, 49 (20.9%) were in second CR and 18 (7.7%) in third or higher CR. With a median follow-up of 21 (1.5-79) months after RIC2, 51 patients are still alive. At 2 years, the cumulative incidence of non-relapse mortality (NRM), relapse incidence (RI), leukaemia-free survival (LFS) and overall survival (OS) were 22.4% (95% confidence interval (CI): 17-28.4), 63.9% (56.7-70.1), 14.6% (8.8-18.5) and 20.5% (14.9-26.1), respectively. In patients with acute myelogenous, biphenotypic and undifferentiated leukaemia (representing 89.8% of all patients), duration of remission following RIC1 4225 days, presence of CR at RIC2, patient's Karnofsky performance status 480 at RIC2 and non-myeloablative conditioning were found to be the strongest predictors of patients' favourable outcome.
INTRODUCTION
Optimal treatment for relapse of acute leukaemia following haematopoietic stem cell transplantation (HSCT) is still poorly defined. Limited therapeutic options are generally available for these patients, and they usually face a very poor prognosis. 1, 2 Depending mostly on the timing of relapse post HSCT, only 10-32% of patients with acute myelogenous leukaemia (AML) can achieve a new remission, whereas prognosis for ALL patients is even worse, with a median overall survival (OS) of about 10 months. 3, 4 Evidence-based treatment strategies do not exist, as most available information is derived from retrospective studies with limited numbers of patients.
Among other risk factors, reduced-intensity conditioning (RIC) has been shown to increase the probability of relapse following transplantation. 3, 5 However, because of its relatively low toxicity, a second RIC allogeneic stem cell transplantation (RIC2) is often the only feasible treatment option, and might be a valuable rescue strategy for a selected group of patients. Namely, a RIC2 HSCT has been shown to be associated with a low and acceptable non-relapse mortality (NRM) in patients who have undergone a previous autologous transplantation, 6, 7 as well as in those who relapse after a previous allogeneic HSCT. 8 A retrospective study of the European Society for Blood and Marrow Transplantation (EBMT) registry data was performed to evaluate the outcome of RIC2 in terms of NRM and overall-and leukaemia-free survival (LFS), as well as to identify prognostic factors that determine the outcome of RIC2 in acute leukaemia patients. Engraftment rate, GVHD and relapse incidence (RI) were also assessed.
MATERIALS AND METHODS

Inclusion criteria and data collection
Data on patients undergoing second allogeneic transplantation using RIC were obtained from the EBMT registry. Patients with acute leukaemia who received a second allograft (RIC2) between 1 January 2000 and 31 December 2012 for relapse of leukaemia after an initial RIC HSCT were included. Data on 250 patients from 101 EBMT transplant centres were initially retrieved from the database, including details on patients' and disease characteristics, type of conditioning, donor relation and source of stem cells that were used. Sixty-one queries were sent out to clarify conflicting entries or inconsistencies, of which 45 were resolved. A total of 16 patients were excluded from further analyses for either entry criteria violation or lack of response to query from center.
End points
All outcomes were calculated from the time of RIC2. NRM was defined as death from any cause without previous relapse or progression; relapse as any event related to recurrence of acute leukaemia; LFS as survival in continuous CR. Relapse or death were considered events, and patients surviving in continuous CR were censored at last follow-up. Haematopoietic recovery was defined as achieving an ANC 40.5/μL and platelets 420/μL. Cumulative incidences of grade 2-4 acute GVHD and of chronic GVHD following RIC2 were also evaluated.
Statistical analysis
The probabilities of OS and LFS were calculated using the Kaplan-Meier method and the log-rank test for univariate comparisons. 9 Cumulative incidence curves were used for RI and NRM in a competing risk setting. 10 Acute and chronic GVHD were diagnosed and graded according to standard criteria. 11, 12 Death was considered as a competing event to GVHD. As the number of ALL patients was relatively low, prognostic factors were studied only in AML patients pooled together with biphenotypic and undifferentiated leukaemia. The log-rank test was used for univariate comparisons and the Gray test for cumulative incidence curves. The following variables were tested in univariate analyses: disease status at RIC1, source of stem cells at RIC1, type of donor at RIC1, presence of acute (grade II or higher) or chronic GVHD before RIC2, age at RIC2, duration of remission following RIC1, interval from relapse to RIC2, female donor to male recipient at RIC2, Karnofsky performance status (480 or ⩽ 80) at RIC2, type of conditioning (RIC vs non-myeloablative) at RIC2, use of TBI for conditioning at RIC2, source of stem cells (BM vs PBSC) at RIC2, type of donor (matched sibling donor (MSD) vs other) at RIC2, donor change at RIC2 compared with RIC1 (MSD at RIC1-same MSD at RIC2 vs MSD at RIC1 -other MSD at RIC2 vs MSD at RIC1-matched-unrelated donor (MUD) at RIC2 vs MUD at RIC1-same MUD at RIC2 vs MUD at RIC1-other MUD at RIC2), disease status at RIC2 and in vivo T-cell depletion at RIC2. The impact of chronic GVHD after second RIC was studied using Therneau's coxph function in R and its extension, the Andersen-Gill model. 13, 14 The Simon and Makuch curve was drawn using a macro developed in R software 3.1.2. (R Development Core Team, Vienna, Austria) to illustrate the effect of GVHD on OS and LFS, using a landmark at 100 days. 15 Adjusted multivariate analyses were performed using a Cox proportional hazards regression model including time-dependent variables. 16 All factors associated with a P-value o0.10 by univariate analysis and chronic GVHD after RIC2 as a time-dependent variable were included in the model. To develop a prognostic classification, a stepwise backward procedure was used on the model including all prognostic factors known at the time of second RIC for OS, with a cutoff significance level of 0.05 for deleting factors in the model. The three remaining significant fixed factors were used to develop a risk score in an additive way. All tests were two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 19 (SPSS Inc./IBM, Armonk, NY, USA) and R 2.13.2 (R Development Core Team) software packages.
RESULTS
Patient and transplant characteristics
During a 13-year period (2000-2012), a total of 234 patients (121 males) with acute myelogenous (205), lymphoblastic (24) , biphenotypic (4) or undifferentiated (1) leukaemia have received RIC2 as a salvage treatment for relapse following RIC1 (Table 1) . Various regimens were used for conditioning; they were fludarabine based in 142 and 110 patients, TBI based in 63 and 45 patients, and other chemotherapy-based conditioning in 15 and 57 cases at first and second transplant, respectively. Second RIC allogeneic transplantation in acute leukaemia patients
Data regarding conditioning at first or second transplantations were missing for 14 and 22 patients, respectively. Cyclosporine A (CSA) in combination with mycophenolate mofetil was used for prevention of GVHD after RIC2 in 32.1%, CSA alone in 23.2% and CSA in combination with methotrexate in 18.5% of the patients.
Other immunosuppressive agents and their combinations were used in the rest of the cases (Table 1) . A total of 44 patients had received donor lymphocyte infusion (DLI) for relapse before the second RIC allogeneic HSCT.
The median age at time of RIC2 was 53 (range 20-74) years. The reasons for RIC were known for 110 (out of 142) patients younger than 55 years: comorbid conditions in 27, prior autograft in 8, protocol driven in 66 and age of recipient (between 50 and 55 years) in 9. The median time from RIC1 to relapse was 220 (range 33-4254) days, and the median time from RIC1 to RIC2 was 359 (range 60-4402) days. At the time of RIC2, 167 (71.4%) patients had relapsed or refractory disease, 49 patients (20.9%) were in second CR and 18 (7.7%) in third or higher CR. The decision to perform RIC2 in all patients was based on clinical judgment of their treating physicians, and patients transplanted in second or higher CR achieved remission following chemotherapy and/or DLI. Stem cells originated from HLA-identical siblings in 43.2% and from unrelated donors in 56.8% of the cases, respectively. Out of the 133 patients who received a second RIC from a non-sibling donor 27 were from haploidentical and 106 from MUDs (HLA was reported for 63 patients; 43 were 10/10; 18 were 9/10 and 2 were 8/8).
The donor at RIC2 was the same as at RIC1 in 84 cases, different in 105 patients, whereas in 48 cases this information was missing. The vast majority of patients (94%) received PBSC for RIC2. Acute and chronic GVHD Grade 2-4 acute GVHD following RIC1 was observed in 13.5% and chronic GVHD after RIC1 (before RIC2) was present in 61 patients (26%). Cumulative incidence of chronic GVHD 2 years after RIC2 was 39.2%.
Outcome
With a median follow-up of 21 (range 1.5-79) months after RIC2, 51 patients were still alive. At 2 years, the rates of NRM, RI, LFS and OS were 22.4% (95% confidence interval (CI): 17-28.4), 63.9% (56.7-70.1), 14.6% (8.8-18.5) and 20.5% (14.9-26.1), respectively. There was no significant difference in survival between ALL patients and others (P = 0.78). Patients with ALL were excluded from further analyses of prognostic factors. In the remaining patients, there was no significant difference in survival according to age (categorized to older or younger than the median-53 years, P = 0.51), type of donor (MSD vs other, P = 0.50), female donor to male recipient (P = 0.63), change of donor at RIC2 (P = 0.95), source of stem cells (bone marrow vs PB, P = 0.71), use of TBI (P = 0.09), in vivo T-cell depletion (P = 0.85) or interval from relapse to RIC2 (shorter or longer than the median-84 days, P = 0.14) ( Table 2 ). Duration of remission following RIC1, disease status at RIC2, patient's performance status at RIC2 and type of conditioning were found to be the strongest predictors of LFS and OS. Patients with an early relapse of their acute leukaemia following RIC1 (defined as shorter than median, i.e. ⩽ 225 days) had significantly higher RI (71% vs 55%; Po 0.001) and lower LFS (7% vs 24%; P o0.001) and OS (10% vs 36%; P o 0.001) 2 years following RIC2 allogeneic transplant (Table 2) . Similarly, patients not being in CR before RIC2 had inferior outcomes compared with those in CR with significantly higher RI (66% vs 56%, P = 0.02) and lower LFS (10% vs 28%, Po 0.001) and OS (16% vs 41%, P o 0.001) 2 years after RIC2 (Table 2) . Patients with better performance status (Karnofsky 480%) at RIC2 had significantly longer LFS and OS (20% vs 8%, P = 0.004, and 29% vs 10%; P o 0.001, respectively). Type of conditioning also had an impact on outcomes following second transplantation-patients conditioned with a non-myeloablative regimen had inferior NRM (12% vs 25%, P = 0.02) and better OS (33% vs 17%, P = 0.02) compared with patients conditioned with a reduced intensity regimen (Table 2) .
In the multivariate model, time from RIC1 to relapse longer than the median and CR at RIC2 were independent prognostic factors associated with lower RI, longer LFS and OS (Table 3) . Chronic GVHD studied as a time-dependent variable (after RIC2) was associated with a better LFS and OS and a trend to a lower RI. Impact of chronic GVHD on OS of AML patients is shown in Figure 1 . An MSD at RIC2 had an independent impact on better OS (Table 3) . Similarly, in vivo T-cell depletion with antithymocyte globulin (ATG) at RIC2 was an independent prognostic factor for longer LFS, and age ⩾ 53 years was independently associated with higher NRM.
Three distinct groups were identified based on the presence or absence of three major risk factors at the time of RIC2, namely time from RIC1 to relapse o225 days, no CR at RIC2 and reduced intensity (vs non-myeloablative) conditioning regimen at RIC2. Patients with none of the mentioned adverse prognostic factors had an overall 2-year survival of 61% (95% CI: 34-88), whereas those with 1 and 2 adverse prognostic factors had OS 46% (95% CI: 28-64) and 12% (95%: CI 7-18), respectively (Figure 2) . Abbreviations: aGVHD = acute GVHD; AML = acute myelogenous leukaemia; ATG = antithymocyte globulin; cGVHD = chronic GVHD; CSA = cyclosporine A; MMF = mycophenolate mofetil; MSD = matched sibling donor; MTX = methotrexate; MUD = matched-unrelated donor; NMA = non-myeloablative; RIC = reduced intensity conditioning; RIC1 = first RIC haematopoietic stem cell transplantation; RIC2 = second RIC transplantation; UD = unrelated donor. a Definition of RIC: busulfan (Bu)+fludarabine (Flu), BuFlu+clofarabine, Bu ± other, fludarbine melphalan (Mel), Mel ± other, treosulfan (Treo), Treo+Flu, cyclophosphamide (Cy)+Flu, Cy+thiotepa, Cy +ARAC, Flamsa TBI, Flamsa Bu, other TBI 4 Gy, Cy TBI, Flu-TBI 4 gy, Flu +thiotepa.
b Definiton of NMA: Flu alone, Flu+ARAC, ARAC+VP16+idarubi-cin, ARAC+clofarabine, clofarabine alone, idarubicin+FLAG, ARAC alone, ARAC+Cy, ARAC+VP16+idarubicin, ARAC+clofarabine, ARAC+amsacrine, ARAC+daunorubicin, ARAC+VP16, ARAC+gemtuzumab, ARAC+idarubicin, TBI alone 2 Gy, Flu-TBI 2 Gy.
Second RIC allogeneic transplantation in acute leukaemia patients R Vrhovac et al Abbreviations: BM = bone marrow; BMT = bone marrow transplantation; LFS = leukaemia-free survival; MSD = matched sibling donor; MUD = matched-unrelated donor; NRM, non-relapse mortality; OS = overall survival; RI = relapse incidence; RIC = reduced intensity conditioning; RIC1 = first RIC haematopoietic stem cell transplantation; RIC2 = second RIC transplantation; UD = unrelated donor.
Second RIC allogeneic transplantation in acute leukaemia patients R Vrhovac et al DISCUSSION RIC allogeneic HSCT with its markedly reduced toxicity in comparison with myeloablative conditioning HSCT, opened new possibilities in the treatment of patients with acute leukaemia, especially older ones and those with comorbidities. However, because of lower conditioning-related direct antileukaemic effect, as well as unfavourable biological features of acute leukaemia in the elderly, an increased relapse rate ranging between 20 and 61% has been seen after RIC. [17] [18] [19] As a consequence, the total number of patients with relapsed acute leukaemia following a first RIC allogeneic HSCT is rising, and their optimal treatment remains challenging. This is the largest study to date on patients with acute leukaemia receiving a second RIC allogeneic transplant after relapse following an initial RIC allograft. Previously reported studies addressed the issue of second transplantation for treating relapsed disease after the first transplant, but the vast majority of Abbreviations: ATG = antithymocyte globulin; cGVHD = chronic GVHD; CI = confidence interval; HR = hazard ratio; LFS = leukaemia-free survival; MSD = matched sibling donor; OS = overall survival; NMA = non-myeloablative; NRM = non-relapse mortality; RI = relapse incidence; RIC2 = second RIC transplantation. a Cox model including all variables and cGVHD after RIC2 in AML.
b Time-dependent variable. Time (years) 1 2 3 Figure 1 . Impact of chronic GVHD on overall survival of AML patients. Overall survival *Adverse prognostic factors include: -time from RIC1 to relapse <225 days -no CR at RIC2 -reduced intensity (vs. non-myeloablative) conditioning regimen at RIC2 Figure 2 . Impact of adverse prognostic factors on overall survival following RIC2 in patients with AML and a relapse after RIC1.
patients received myeloablative conditioning, but not RIC at first transplant. 8, [20] [21] [22] [23] [24] Furthermore, only more recent studies included also transplants from unrelated donors at RIC2. 8, 25, 26 Historically, retransplantation with a second myeloablative conditioning was complicated by high rates of NRM, reported to be up to 46%. 19, 23, 27 The largest study investigating the outcome of a RIC2 following an initial myeloablative transplant included 71 patients (the majority of them having leukaemia or myelodysplasia) and demonstrated acceptable TRM (24% at 1 year), comparable to the one expected after the initial myeloablative transplant procedure. 8 Eapen et al. 28 reported a 1-year TRM of 26% in a group of 279 patients treated with second allogeneic HSCT, 45 of which of the RIC type. Christopoulos et al. 25 retrospectively analysed 58 patients receiving a second allograft for AML relapse after the first (mostly myeloablative conditioning) transplantation, reporting a TRM of 31.4% at 3 years, most of it occurring in the first 6 months following RIC2. Christopeit et al. 26 performed a retrospective registry study on 179 patients with relapsed acute leukaemia treated with a second allogeneic HSCT, 33% of them receiving RIC at second transplantation. NRM after second transplantation was 31.8% for the whole group. Selecting a new donor for second transplantation, which was done in 54.2% of these patients, did not result in a relevant improvement in overall survival. 26 Two other studies on small number of patients also reported low TRM after RIC transplant for the treatment of relapse following a myeloablative transplant. 29, 30 Our study suggests that a RIC regimen for the first allogeneic HSCT further reduces overall transplant-related toxicity, making a second RIC transplant feasible for a significant number of patients.
The results of our study also clearly demonstrate that AML patients with delayed relapses after RIC1, those with chemosensitive disease and good performance status at RIC2 are those who benefit the most from a second RIC transplantation. Furthermore, our study shows that in this patient population nonmyeloablative conditioning at second transplantation reduces NRM by more than a half, which translates into longer LFS and OS.
Regarding timing of relapse, in our study the difference in overall survival was noted after 225 days (7.5 months), which was also the median time of relapse occurrence following RIC1. Duration of remission following first transplant was the factor that greatly impacted outcome of patients after the second allograft in other reported series, as well. 8, 20, 23, 28, 31 Timing of relapse following transplantation is a very robust and consistent prognostic factor for overall outcome. It is interesting to note that Levine et al. 32 found also that AML patients who relapsed 6 months or later following allogeneic HSCT were almost four times more likely to achieve remission compared with those who relapsed in the first 6 months following allogeneic HSCT. 32 In addition, a large retrospective study on 399 patients with relapsed AML following allogeneic HSCT by Schmid et al. 33 demonstrated that patients who received DLI and chemotherapy did better than those treated with chemotherapy alone. The use of DLI retained significance on multivariate analysis in this study but was not as important as younger age or time of relapse 45 months post allogeneic HSCT. Notably, the benefit of DLI in this study was greatest for those patients who attained a second CR before DLI.
Importance of chemosensitivity of the disease in our study is also in line with results published by other groups that have investigated second (or subsequent) allogeneic transplantations and the influence of disease burden on the outcome. Long-term survival was very poor in patients who did not achieve remission of their disease before RIC2. This finding is consistent with data from other reports on relapse after RIC. 33, 34 Kishi et al. 31 and Mrsic et al. 35 demonstrated that acute leukaemia in remission before the second transplant is a factor clearly correlated with better outcome. Kedmi et al. 36 retrospectively analysed the outcome after second or subsequent allogeneic transplantation for different indications, and found that factors indicating higher likelihood for survival were a non-malignant disease, full HLA-matching, the use of RIC and a non-relapse indication. Furthermore, patients with resistant malignancies who did not respond to chemotherapy had a lower chance to respond to a second transplant procedure. Hosing et al. 37 also found that patients with AML/MDS have better outcome after a second transplant if they start the procedure with lower disease burden, defined as the absence or o5% blasts in the peripheral blood.
Chemotherapy used for the treatment of patients who had relapsed after RIC1 has not been investigated in our study. Successful salvage with FLAG-Ida (fludarabine, cytarabine and idarubicin), MEC (mitoxantrone, etoposide and cytarabine) or similar combination chemotherapy followed by RIC allograft has been reported in small series of patients. 2, 29, 38 The intensity of chemotherapy should be adjusted depending on the timing of relapse and medical condition of the patient, as tolerance to chemotherapy in the early post-transplant setting is generally poor and can lead to severe complications. Because of the retrospective nature of our study, patients who remained in remission long enough to get a RIC2 represent a selected group.
Presence of chronic GVHD was reported by some groups as a favourable prognostic factor for survival, 20, 23 which has been confirmed by our study as well. Time dependent analysis on the impact of chronic GVHD on outcome of our patients clearly demonstrated its association with a trend to a lower RI and a better LFS, and had a clear, statistically significant association with a better OS. Although univariate analyses did not reveal positive prognostic influence of an MSD at RIC2 on outcome, in a multivariate model, an MSD at RIC2 was found to be a favourable prognostic factor for OS.
Other factors were not found to influence outcome in our series of patients. Change of donor at second transplantation, and female to male donor vs others also did not have a significant prognostic value in multivariate analyses.
Based on our results, future prospective clinical trials could address the role or RIC2 allogeneic HSCT in acute leukaemia patients relapsing after RIC1 by investigating: second RIC allogeneic HSCT vs more 'conservative' treatment, that is, chemotherapy+DLI approach; intensity of conditioning (reduced toxicity vs reduced intensity vs non-myeloablative) in fit patients, or RIC2 only in patients achieving CR after chemo and/or DLI vs straight sequential FLAMSA (or similar) allogeneic HSCT approach.
CONCLUSIONS
Overall, our findings suggest that a second RIC transplant is a feasible rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation, especially if compared with historical data from standard myeloablativeconditioning second allogeneic HSCT. Of note, fit AML patients who relapse beyond 7.5 months after a first RIC allogeneic HSCT and those with chemosensitive disease are potential candidates for a second RIC allogeneic HSCT with an acceptable rate of NRM. Non-myeloablative conditioning regimens seem to provide a good balance of efficacy and toxicity in this setting. Conversely, there is no solid evidence that other groups of patients with relapsed acute leukaemia following RIC1 could benefit from an RIC2, and these should therefore be considered for investigational therapies in the context of well-designed clinical trials.
